Perspectum Diagnostics has announced a new partnership with QuintilesIMS, bringing together breakthrough technology solutions with global operational excellence to accelerate Nonalcoholic steatohepatitis (NASH) clinical trial development.

Nonalcoholic steathohepatitis (NASH) is a type of Nonalcoholic fatty liver disease (NAFLD), a condition in which fat builds up in the liver. If NAFLD progresses to NASH it typically means the patient has developed inflammation and liver cell damage in addition to the fat build up.

Both NAFLD and NASH are associated with obesity and diabetes, conditions which are on the increase globally. If left untreated the condition can progress into cirrhosis of the liver or cause associated health problems such as cardiovascular disease. Whilst losing weight is an effective treatment option for patients diagnosed with NASH it has limited rates of adherence and there are no pharmaceuticals to support treatment efforts. It is predicted that by 2020 NASH will be the leading cause of liver transplants.

By partnering with QuintilesIMS, Perspectum Diagnostics aim to accelerate the pharmaceutical trials process to bring a treatment to market by 2021-2022. Their novel product LiverMultiScan works with current MR technology to provide a non-invasive method of screening patients with liver disease, avoiding the need for invasive liver biopsies which have poor patient take-up rates. QuintileIMS offer a huge wealth of patient data through its network and the partnership will help to identify patient groups suitable for clinical trials in addition to spotting trends and validating the data.

For more information please visit:

Perspectum Diagnostics

QuintilesIMS

Information Leaflet [pdf]